Albatroz Therapeutics

What Albatroz Therapeutics does

Albatroz Therapeutics Pte. Ltd. is a Singapore-based, pre-clinical biotechnology company founded in 2020 as a spin-off from A*STAR's Institute of Molecular and Cellular Biology (IMCB). The company is developing first-in-class therapeutic antibodies that block Calnexin, a tumor surface protein critical to extracellular matrix (ECM) degradation, under an exclusive license to the related patent portfolio covering the GalNAc-T Activation (GALA) glycosylation pathway discovered by co-founder Dr. Frederic Bard. Its pipeline comprises three core anti-Calnexin antibody programs targeting solid tumors (pancreatic, lung, liver), arthritis (osteoarthritis and rheumatoid arthritis via prevention of cartilage degradation), and inflammatory bowel disease (Crohn's and ulcerative colitis). The April 2025 Nature Communications publication, co-authored with Roche's pRED Innovation Center, demonstrated arthritis disease-modifying potential and absence of detectable in vivo toxicity, addressing a key limitation of prior ECM-targeting candidates.

The company's core technology comprises a suite of monoclonal antibodies raised against cell-surface Calnexin, which is selectively exposed in tumors and arthritic synovial membranes, enabling selective targeting with minimal off-target effects. In vitro and in vivo preclinical toolkits support target validation and candidate optimization, and the antibody engineering effort is led by Cheng-I Wang (formerly founder of Euchloe Bio). Albatroz has secured recognition including the inaugural Amgen Golden Ticket in Singapore, a one-year NSG BioLabs BSL-2 laboratory residency, JLABS Singapore membership, and admission to the 2020 BRACE Award Venture Competition finals. Scientific advisors include former Roche R&D executives and other pharma operators, providing late-stage development perspective.

Albatroz operates a sales-led, partnership-driven business model targeted at pharmaceutical and biotech companies, with no commercial products, no disclosed pricing, and no end-customer revenue. Headquartered at 160 Robinson Road, Singapore, and embedded in the Biopolis ecosystem, the company's go-to-market relies on conference participation (e.g., Novo Nordisk Singapore Partnering Day 2023), scientific publications, earned media, and licensing and co-development partnerships as its primary distribution channel. Future revenue is expected to be generated through licensing deals, co-development arrangements with pharmaceutical partners, and eventual drug commercialization, but no such deals have been disclosed to date. The company is privately held and venture-backed, with a single $3 million USD seed round led by Outram Bio and SEEDS Capital closed in April 2023.

Name

Albatroz Therapeutics

Legal name

Albatroz Therapeutics Pte. Ltd.

Website

https://albatroztherapeutics.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Albatroz Therapeutics is a Singapore-based pre-clinical biotech developing first-in-class anti-Calnexin antibodies for solid tumors, arthritis, and inflammatory bowel disease, spun out from A*STAR's IMCB and partnering with pharmaceutical companies for licensing and co-development.

Ownership category

akta.pro rank

Product category

Therapeutic Antibodies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Therapeutic antibodies
• Oncology drug discovery
• Anti-calnexin therapeutics
• Extracellular matrix research
• Pre-clinical biotechnology

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Therapeutic Antibody Licensing/Partnerships: Pre-clinical stage biotech company developing first-in-class antibody therapeutics. Revenue expected to be generated through licensing deals, co-development partnerships with pharmaceutical companies, and ultimately drug commercialization. The company is actively pursuing collaboration with pharmaceutical and biotech innovators to maximize impact.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Albatroz Therapeutics is a pre-clinical stage biotechnology company developing first-in-class therapeutic antibodies that target Calnexin, a novel tumor surface protein driving extracellular matrix degradation. Its three core pipeline programs address solid tumor growth and metastasis, cartilage destruction in osteoarthritis and rheumatoid arthritis, and tissue damage in inflammatory bowel disease (Crohn's disease, ulcerative colitis). The company is advancing these antibody candidates toward clinical development through partnerships and licensing arrangements with pharmaceutical companies.

Product overview

Albatroz Therapeutics is developing first-in-class therapeutic antibodies against Calnexin, a novel target critical to extracellular matrix degradation. The company's portfolio consists of three core product candidates targeting different therapeutic areas: (1) Anti-Calnexin Therapeutic Antibodies for Cancer, which prevent tumor growth, metastasis, and recurrence in solid tumors; (2) Anti-Calnexin Therapeutic Antibodies for Arthritis, which prevent cartilage destruction in osteoarthritis and rheumatoid arthritis; and (3) Anti-Calnexin Therapeutic Antibodies for Inflammatory Bowel Disease, which halt disease progression in Crohn's disease and ulcerative colitis. All products leverage the same Calnexin-targeting platform technology, which was developed by the founders at A*STAR's Institute of Molecular and Cellular Biology and provides high specificity with minimal toxicity profiles.

Differentiator

Problem solved

Functional benefit

Products and services

• Anti-Calnexin Therapeutic Antibodies for Cancer First-in-class therapeutic antibodies blocking Calnexin to prevent solid tumor growth, metastasis, and recurrence, with demonstrated potency against pancreatic, lung, and liver tumor models and no detectable toxicity in vivo. Aimed at pharmaceutical partners for licensing and co-development.
• Anti-Calnexin Therapeutic Antibodies for Arthritis First-in-class therapeutic antibodies blocking Calnexin on arthritic synovial fibroblasts to prevent cartilage destruction in osteoarthritis and rheumatoid arthritis. Published Nature Communications data indicates the antibodies may reverse disease progression. Targeted at pharmaceutical partners for clinical advancement.
• Anti-Calnexin Therapeutic Antibodies for Inflammatory Bowel Disease First-in-class therapeutic antibodies targeting Calnexin to halt progression of inflammatory bowel disease, including Crohn's disease and ulcerative colitis, by preventing destruction of the intestinal lining and enabling intestinal healing. Targeted at pharmaceutical partners for licensing and co-development.

Quantifiable outcome

• Anti-Calnexin antibodies demonstrated first-in-class therapeutic potential in animal models of arthritis, blocking cartilage extracellular matrix breakdown
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Ten partnerships are on record, tiered major, minor and core.

• Roche – Pharma Research & Early Development (pRED) Innovation CentermajorStrategic or Co-development Partner · 10 April 2025Researchers from Roche's pRED Innovation Center in Basel, Switzerland co-authored the Nature Communications paper on Calnexin inhibition in arthritis. Virginie Sandrin, Senior Principal Scientist and Project Team Leader at Roche, co-authored the pivotal publication, indicating a co-research collaboration.
• Institute of Molecular and Cell Biology (IMCB), A*STARmajorStrategic or Co-development Partner · 10 April 2025IMCB is the A*STAR institute where Albatroz's founders discovered the GALA glycosylation pathway and Calnexin target. Ongoing research collaboration includes studies on synovial fibroblasts and cartilage degradation in arthritis.
• Tan Tock Seng Hospital (TTSH)minorStrategic or Co-development Partner · 10 April 2025Researchers from Tan Tock Seng Hospital collaborated on the Nature Communications publication on Calnexin inhibition in arthritis.
• Cancer Research Center of Marseille (CRCM)minorStrategic or Co-development Partner · 10 April 2025Researchers from the Cancer Research Center of Marseille collaborated on the pivotal Nature Communications publication on Calnexin inhibition in arthritis. Dr. Frederic Bard also serves as Director of Research at the Cancer Research Centre in Marseille.
• Johnson & Johnson Innovation – JLABS SingaporemajorStrategic or Co-development Partner · 29 August 2024Albatroz became a member of Johnson & Johnson Innovation – JLABS Singapore, gaining access to mentorship, infrastructure, and industry connections that will propel the company's groundbreaking therapies toward the clinic. JLABS Singapore is part of a global network of life science incubators.
• A*STAR – Agency for Science, Technology and ResearchcoreStrategic or Co-development Partner · 7 November 2023A*STAR is Albatroz's founding institution and continues to be a key partner. The novel technology was developed at IMCB, A*STAR, and Albatroz holds an exclusive license for rights to the technology patent portfolio. Dr. Bard worked at IMCB, A*STAR for over a decade developing the GALA pathway technology.
• Novo NordiskminorGTM or Marketing Partner · 10 October 2023Albatroz was featured at the Novo Nordisk Singapore Partnering Day 2023, invited to participate in partnering, networking, and relationship building with global biotechnology companies as part of the Singapore biotech ecosystem.
• Frankfurt School of Finance and ManagementminorGTM or Marketing Partner · 12 September 2023Albatroz's Co-Founder and CBO Guy Heathers presented at the 'Biomedical Innovation in Asia' workshop organized by the Frankfurt School of Finance and Management's Asia Healthcare Innovation Day 2023.
• AmgenmajorStrategic or Co-development Partner · 19 March 2023Albatroz won the first Amgen Golden Ticket in Singapore, evaluated by Amgen's internal scientific committee for scientific rationale, subject matter expertise, and business plan viability. The prize provides access to Amgen's vast network of scientific and business leaders. Amgen is a leading global biotechnology company committed to discovering, developing and delivering innovative human therapeutics.
• NSG BioLabsmajorStrategic or Co-development Partner · 19 March 2023NSG BioLabs, Singapore's largest provider of biotech co-working laboratories and offices, partnered with Amgen to award Albatroz a one-year free residency in their fully-equipped, turnkey, and certified BSL-2 laboratory as part of the Amgen Golden Ticket prize. NSG BioLabs is located at Biopolis, Singapore's premier research hub.

Scale indicators7 records

Recent moves7 records

Expansion highlights4 records

Broad incumbents

• AbbVie: Global biopharmaceutical company and leader in immunology with Humira and other anti-inflammatory antibody biologics dominating the arthritis and IBD markets. Represents the dominant incumbent in Albatroz's primary therapeutic areas.
• Amgen: Global biotechnology leader with major oncology (Blincyto, Lumakras) and inflammation (Enbrel, Otezla) franchises. Comparable as a broad incumbent in Albatroz's target indications and a known ecosystem partner (Amgen Golden Ticket awarder).
• Roche: Global pharmaceutical and diagnostics leader with deep oncology and immunology pipelines. Directly comparable as both a research collaborator (pRED co-authored the Nature Communications paper) and the dominant incumbent whose franchise Albatroz's Calnexin mechanism could complement or compete with.
• Johnson & Johnson (Innovative Medicine): Global healthcare conglomerate with major immunology (Stelara, Tremfya, Remicade) and oncology (Darzalex, Erleada) franchises. Comparable as a broad incumbent in Albatroz's target indications and an active ecosystem partner via J&J Innovation – JLABS Singapore membership.

Direct peers

• Hummingbird Bioscience: Singapore-headquartered precision antibody biotechnology company developing first-in-class therapeutics against novel oncology targets. Closely comparable to Albatroz in stage (clinical), therapeutic modality (antibodies), geography (Singapore), and approach (novel targets identified through academic research collaborations).
• Adagene: Singapore and San Diego-based clinical-stage antibody discovery and engineering company developing potent and precise therapeutics in oncology. Comparable in antibody platform approach, Singapore roots, and partnership-driven business model.
• Enleofen Bio: Singapore-based preclinical antibody biotechnology company developing anti-IL-11 therapeutics for fibro-inflammatory diseases including cancer and fibrosis. Comparable in therapeutic modality (antibodies), disease areas (ECM-related pathologies), stage, and Singapore ecosystem participation.

Emerging players

• Black Diamond Therapeutics: Clinical-stage precision oncology company developing allosteric small molecule therapies. Comparable as an early-stage oncology biotech that IPO'd through traditional biotech pathway, with overlapping leadership pedigree (Albatroz advisor Roberto Iacone was part of the founding leadership team).
• Bright Peak Therapeutics: Versant Ventures-incubated biotech developing next-generation immunotherapies and antibody therapeutics. Comparable as an early-stage antibody biotech with shared academic pharma R&D pedigree (co-founded by Albatroz advisor Roberto Iacone).

Regional players

• Tessa Therapeutics: Singapore-based clinical-stage cell therapy company. Regional peer with shared Singapore biotech ecosystem, similar academic spin-out origins (A*STAR-adjacent), and overlapping management/advisor networks (Albatroz CBO Guy Heathers advises Tessa).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/albatroz-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Albatroz Therapeutics